SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.

The NIH data shows that the NIH – created COVID-19 spike protein when dosed at either 0.1 or 1.0 mcg and combined with an adjuvant completely inhibited virus growth in the nasal cavities and lungs of mice when the animals were infected four weeks after their second immunization, compared to the unvaccinated control animals. The adjuvant uses was TLR-4-agonist Sigma Adjuvant System – a TLR-4 agonist that induces T cell activation in mice. Adjuvants are added to vaccines to boost immune responses.

Learn more about SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice.